

Prof. Robert M. Mader, D. Sc.
Clinical Division of Oncology, Department of Medicine I
Comprehensive Cancer Center of the Medical University of Vienna
Austria



Curriculum Vitae

Name: Robert M. Mader
Date of birth: November 17, 1957
Place of birth: Vienna
Nationality: Austrian

Education:

1986 Graduation as D.Sc. in Technical Chemistry (*Dr.techn.rer.nat.*)
1983 Graduation with Diploma in Technical Chemistry (*Dipl.Ing.*)

Appointments:

from 2010 Director for Translational Research at the Department of Medicine I, Medical University of Vienna
from 1997 Associate professor and Program Director for "Molecular Pharmacology" at the Department of Medicine I, Clinical Division of Oncology, Vienna University School of Medicine (since 2004: Medical University of Vienna)
1995-1997 Head of the study group "Molecular Pharmacology" at the Department of Medicine I, Division of Oncology, Vienna University School of Medicine
1986-1995 Research scientist at the Department of Medicine I, Division of Oncology, Vienna University School of Medicine

Additional training: Project management (certified project manager), GCP, "First in human studies", Quality assurance in biotechnology, Management of research teams Medical Writing at EMWA (European Medical Writers Association, ongoing)

Activities as chair:

from 2014 Member of the Management Board of GPMed, Gesellschaft für Pharmazeutische Medizin e.V. (Society of Pharmaceutical Medicine)
from 2010 Coordinator of the Research Cluster "Experimental Therapy and Drug Resistance" at the Comprehensive Cancer Center Wien
2013-2014 Coordinator of the Task Force „Extravasation" at the Comprehensive Cancer Center Vienna
2005-2011 Chairmen/Vice-Chairmen of the Working Group Pharmacology in Oncology/Hematology of CESAR (Central European Society for Anticancer Research)
2003-2009 Head of the Task Force "Tumour bank of the ABCSG" (Austrian Breast and Colorectal Cancer Study Group)

Selected projects

Coordinator: "The function of microRNAs as regulators of stress tolerance in cancer models" funded by FWF, project P23954-B20 (2012-2015)

Co-PI: "microRNA in colorectal cancer and their correlation with predictive and prognostic markers" funded by NÖ Forschungs- und Bildungsges.m.b.H, project LS10-021 (2012-2014)

Coordinator: "Tumour specific activation of suicide genes as treatment option for malignant diseases" funded by Jubiläumsfonds der Österreichischen Nationalbank as coordinator (2006-2008)

Cooperations

Prof. Georg Krupitza, Med. Univ. Vienna: experimental cancer therapy; **Prof. Günther Steger**, Med. Univ. Vienna: clinical trials in breast and colon cancer; **Prof. Johannes Grillari**, University of Natural Resources and Life Sciences Vienna: microRNA; **Prof. Ioannis Tentis**, Democritus University of Thrace, Greece: drug resistance.

More information on LinkedIn:

https://www.linkedin.com/profile/view?id=204580881&trk=nav_responsive_tab_profile&locale=en_US

Selected References

- Prager GW, Unseld M, Waneck F, Mader RM, Baumann L, Müllauer L, Zielinski CC: Results of the Extended Analysis for Cancer Treatment (EXACT) trial: A Prospective Translational Study Evaluating Individualized Treatment Regimens in Oncology. *Oncotarget*, in press
- Stübiger G, Nairn MD, Abban TK, Openshaw ME, Mancera L, Herzig B, Wuczkowski M, Senfter D, Mader RM. MALDI-MS protein profiling of chemoresistance in extracellular vesicles of cancer cells. *Anal Chem* 90(22): 13178-13182 (2018); doi: 10.1021/acs.analchem.8b03756
- Schoergenhofer C, Schwameis M, Firbas C, Bartko J, Derhaschnig U, Mader RM, Sunder Plaßmann R, Jilma-Stohlawetz, Desai K, Proiya M, Jäger U, Jilma B: Single, very low rituximab doses – a pilot and a randomized trial: implications for dosing and biosimilarity testing. *Scientific Reports* 8: 124 (2018)
- Catana CS, Pichler M, Giannelli G, Mader RM, Berindan-Neagoe I: Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma. *Oncotarget*, 8: 29519-29534 (2017)
- Holzner S, Senfter D, Stadler S, Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S, Jäger W, Dolznig H, Mader RM, Krupitza G: Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro. *Oncol Rep* 36: 3065-3071 (2016); doi: 10.3892/or.2016.5114
- Körber MI, Staribacher A, Ratzenböck I, Steger G, Mader RM: NFκB-associated pathways in progression of chemoresistance to 5-fluorouracil in an in vitro model of colonic cancer. *Anticancer Res* 36: 1631-1640 (2016)
- Fetahu IS, Tennakoon S, Lines KE, Groeschel C, Aggarwal A, Mesteri I, Baumgartner-Parzer S, Mader RM, Thakker RV, Kállay E: miR-135b- and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal cancer. *Int J Cancer* 138: 137-145 (2016); doi: 10.1002/ijc.29681
- Senfter D, Holzner S, Kalipcian M, Staribacher A, Walzl A, Huttary N, Krieger S, Brenner S, Jäger W, Krupitza G, Dolznig H, Mader RM: Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. *Human Mol Genet* 24: 3689-3698 (2015); doi:10.1093/hmg/ddv113
- Egger AE, Kornauth C, Haslik W, Hann S, Theiner S, Bayer G, Hartinger CG, Keppler BK, Pluschnig U, Mader RM: Extravasation of Pt-based Chemotherapeutics – Bioimaging of their Distribution in Resectates by Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry (LA-ICP-MS). *Metallomics* 7: 508-515 (2015); doi:10.1039/c4mt00308j
5. Haslik W, Pluschnig U, Giessrigl B, Schmidt W, Kalipcian M, Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader R, Krupitza G: Fulvestrant induces resistance by modulating GPER and CDK6 expression; implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. *Br J Cancer* 109: 2751-2762 (2013)
- Hobl E-L, Jilma B, Erlacher L, Duhm B, Mustak M, Broell H, Hoegger P, Rizovski B, Mader RM: A Short-chain Methotrexate Polyglutamate as Outcome Parameter in Rheumatoid Arthritis Patients Receiving Methotrexate. *Clin Exp Rheumatology* 30: 156-163 (2012)
- Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Gnant M, Mader RM, Zielinski CC, Steger GG: Impact of systemic anti-her2 therapy on overall survival in patients with brain metastases from her2-overexpressing breast cancer. *Br J Cancer* 106: 25-31 (2012)
- Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, Kalt R, Krieger S, Vo TPN, Madlener S, Bauer S, Marian B, Hämmerle M, Kretschy N, Teichmann M, Hantusch B, Stary S, Unger C, Seelinger M, Eger A, Mader R, Jäger W, Schmidt W, Grusch M, Dolznig H, Mikulits W, Krupitza G: NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. *Br J Cancer* 105: 263-271 (2011)
- Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, Mader RM: Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. *Exp Cell Res* 316: 3172-3181 (2010)



Robert Mader

Vienna, January 23, 2019

More information on LinkedIn:

https://www.linkedin.com/profile/view?id=204580881&trk=nav_responsive_tab_profile&locale=en_US